HemOnc Today

CURRENTLY VIEWING:

The following articles appeared in the print edition of HEMONC TODAY.

Table of Contents
Cover Story

In ‘big medicine’ era, innovation essential to sustainability of independent practices

Editorial

Cancer progress reports: The gap between discovery and delivery

John Sweetenham, MD

FDA approvals

FDA approves Keytruda for advanced melanoma

FDA approves Eliquis for treatment of DVT, PE

FDA expands approval of Promacta

Health Care Updates

Report: Commitment to NIH, NCI funding only 'viable path' for continued success in cancer research

In the Journals

Preoperative radiation improved survival in malignant pleural mesothelioma

Panitumumab regimen improved OS in metastatic colorectal cancer

IGH@ translocations linked to poor ALL outcomes in adolescents, young adults

Erlotinib no better than docetaxel in advanced NSCLC

Co-existence of BRAF V600E, TERT promoter mutations predict recurrence in papillary thyroid cancer

Sirolimus failed to reduce GVHD rates after HSCT

Elacytarabine failed to improve outcomes in relapsed/refractory AML

Comorbid conditions determined appropriate age for cancer screening cessation

Cancer center advertisements appealed to emotions but lacked data on costs, risks

US cancer survivors at risk for financial hardships

Investigational prostate cancer drug decreased PSA levels with low toxicity

Conformal radiation therapy improved NSCLC survival

Anemia treatment not beneficial after brain injury

Late chemotherapy increased in-hospital death risk among terminally ill patients

Enzalutamide safe, effective in hormone-naive prostate cancer

Ipilimumab yielded no major benefit in prostate cancer bone metastases

Immunotherapy, BRAF inhibitor sequence affected outcomes in metastatic melanoma

HPV persists significantly longer in black women

Institution Notes

ASH to honor several hematology leaders

BRCA research center to present second annual prize

Radiation oncologist receives ACRO medal

Meeting News Coverage

Single-fraction radiation effective for bone metastases

Eribulin plus trastuzumab safe, effective in HER-2–positive metastatic breast cancer

MM-398 plus chemotherapy extended OS, PFS in metastatic pancreatic cancer

Model predicted likelihood of ADH upgrade to cancer

Everolimus plus exemestane extended PFS in invasive lobular carcinoma

BRCA mutation incidence comparable between ER-negative, ER-low–positive breast tumors

Cryoablation plus ipilimumab induced immune responses in early-stage breast cancer

Shorter ADT regimen improved quality of life among men with high-risk prostate cancer

Tumor subtype predicted survival after WBRT for metastatic breast cancer

Physician-signed reminder letters improved mammography rates among overdue women

Neoadjuvant chemotherapy response predicted locoregional breast cancer recurrence

Nomogram predicted risk for locoregional recurrence